Mark Wefers Bettink

Mitochondrial oxygen monitoring during surgical repair of congenital diaphragmatic hernia or esophageal atresia: 9 177 skin can be done without harm, it requires planning and currently prevents its use in emergency situations. In elective situations in the operating room and for use in the intensive care this proved not a major issue. In conclusion, this is the first study showing it is possible to measure mitoPO 2 in neonates and that the cutaneous administration of ALA to neonates in the described situation can be safely applied. Preliminary data suggests that mitoPO 2 in neonates responds to perturbations in physiological status. The added value of mitochondrial measurements for clinical decision making remains to be determined in future studies. Conflict of Interest Dr. E.G. Mik is founder and shareholder of Photonics Healthcare B.V., The company that developed and commercializes the COMET monitor. Photonics Healthcare B.V. holds the exclusive licenses to several patents regarding this technology, filed and owned by the Academic Medical Center in Amsterdam and the Erasmus University Medical Center Rotterdam, the Netherlands. The remaining authors declare that they have no competing interests. Author Contributions All authors had a substantial contribution to conception and design, and/or acquisition of data, and/or analysis and interpretation of data. All authors participated in drafting the article or revising it critically for important intellectual content and gave final approval of the version to be submitted. Funding None. Acknowledgments None.